Palisade Bio (NASDAQ:PALI) Posts Earnings Results, Beats Estimates By $1.70 EPS

Palisade Bio (NASDAQ:PALI) announced its quarterly earnings data on Monday. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($2.39) by $1.70, Zacks reports.

Palisade Bio Trading Down 1.4 %

NASDAQ:PALI opened at $0.70 on Tuesday. The stock has a 50-day moving average price of $1.12 and a 200 day moving average price of $2.17. Palisade Bio has a 12-month low of $0.66 and a 12-month high of $9.65. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.05 and a beta of 1.49.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.